Structure Therapeutics

Historical price data

Structure Therapeutics is on a mission to develop best-in-class oral small molecule therapeutics for validated but challenging G protein-coupled receptor (GPCR) targets, primarily in large markets like obesity and diabetes. Since its 2016 founding, the company has rapidly advanced a promising pipeline, most notably its GLP-1 receptor agonist GSBR-1290, and achieved a successful public listing, reflecting strong investor confidence in its differentiated structural biology platform. Its strategy hinges on using atomic-level insights to design superior oral drugs that could capture significant market share from incumbent injectable therapies.

An integrated structure-based drug discovery platform combining cryo-electron microscopy (cryo-EM) for atomic-level GPCR visualization with advanced computational modeling and machine learning to design oral small molecule therapeutics.

Structure competes directly with major pharma (Novo Nordisk, Eli Lilly) in the obesity/diabetes space and other biotechs with oral GLP-1 candidates. Its differentiation lies in its structure-based platform for designing optimized oral small molecules, but it must demonstrate superior clinical profiles to succeed.